The biologics CDMO will install a 2,000L single-use bioreactor (SUB) from Thermo Fisher Scientific at its Berkeley facility to meet demand for early-phase projects.
ABEC has expanded manufacturing in Ireland with the completion of an ISO-7 cleanroom, where the single-use vendor will make disposable bioreactor bags for global distribution.
The manufacturing contract is the first of what Samsung BioLogics expects to be a number of long-term partnerships at its recently completed 180,000L facility.
Repligen says the single-use version of its alternating tangential flow (ATF) platform is helping the firm capture a larger share of the fed-batch bioreactor marketplace.
“There is a new kid on the block to rival E. Coli, CHO and yeast,” says Dyadic International as it collaborates to widen the use of its C1 expression tech.
A warning letter at manufacturing partner Celltrion could delay approvals of the potential migraine prevention monoclonal antibody fremanezumab and two biosimilar candidates, says Teva.
Catalent has partially attributed a 26% year-on-year growth in its Drug Delivery Solutions segment to the acquisition of Cook Pharmica, which closed in the quarter.
AbSci says its genetically engineered E. coli expression platform has produced yields exceeding 20 g/L for difficult to express products and threatens the dominance of mammalian systems.
Adaptimmune Therapeutics has manufactured the first SPEAR-T cells for a patient at its Navy Yard facility, which will be the primary site for its future manufacturing requirements.
Partner Therapeutics (PTx) has acquired the rights to Sanofi’s FDA-approved human growth factor Leukine along with a dedicated manufacturing plant in Washington state.
Amgen has announced plans for a US biomanufacturing facility, similar to its flexible and single-use Singapore plant, as part of $3.5bn freed through tax reforms.
